190 related articles for article (PubMed ID: 11927281)
1. Aromatase inhibitors continue their ATAC on tamoxifen.
Nicholls H
Trends Mol Med; 2002; 8(4 Suppl):S12-3. PubMed ID: 11927281
[No Abstract] [Full Text] [Related]
2. [Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Bergmann L
Strahlenther Onkol; 2001 May; 177(5):273-4. PubMed ID: 11398617
[No Abstract] [Full Text] [Related]
3. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
4. Should aromatase inhibitors replace tamoxifen?
Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy in early and advanced breast cancer.
Buzdar AU
Breast J; 2004; 10 Suppl 1():S19-21. PubMed ID: 14984485
[TBL] [Abstract][Full Text] [Related]
6. Role of anastrozole in adjuvant therapy for postmenopausal patients.
Buzdar AU
Semin Oncol; 2003 Oct; 30(5 Suppl 16):21-9. PubMed ID: 14613023
[TBL] [Abstract][Full Text] [Related]
7. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
8. Adjuvant aromatase inhibitors: are we there yet?
Fleming GF
Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
[No Abstract] [Full Text] [Related]
9. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP; Hudis C; Burstein HJ; Chlebowski RT; Ingle JN; Edge SB; Mamounas EP; Gralow J; Goldstein LJ; Pritchard KI; Braun S; Cobleigh MA; Langer AS; Perotti J; Powles TJ; Whelan TJ; Browman GP
J Clin Oncol; 2002 Aug; 20(15):3317-27. PubMed ID: 12149306
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy in postmenopausal breast cancer.
Ingle JN
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):480S-5S. PubMed ID: 12538504
[TBL] [Abstract][Full Text] [Related]
11. Hormones 'R' us.
Sledge GW
Clin Breast Cancer; 2002 Jan; 2(4):251. PubMed ID: 11899355
[No Abstract] [Full Text] [Related]
12. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K; Brown P
J Natl Cancer Inst; 2003 Jun; 95(11):766-7. PubMed ID: 12783921
[No Abstract] [Full Text] [Related]
13. Current developments in hormonal therapy of breast cancer.
Buzdar AU
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
[No Abstract] [Full Text] [Related]
14. ATAC trial update.
de Castro G
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
[No Abstract] [Full Text] [Related]
15. The current status of aromatase inhibitors in the management of breast cancer.
Baum M; Buzdar A
Surg Clin North Am; 2003 Aug; 83(4):973-94. PubMed ID: 12875605
[TBL] [Abstract][Full Text] [Related]
16. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
17. Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Doggrell SA
Expert Opin Pharmacother; 2008 Jun; 9(9):1619-22. PubMed ID: 18518790
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors in breast cancer: an update.
Lake DE; Hudis C
Cancer Control; 2002; 9(6):490-8. PubMed ID: 12514567
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
Munster PN; Horton J
Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
[No Abstract] [Full Text] [Related]
20. [National Conference of Medical Oncology. Controversies in the treatment of breast cancer. Genova, October 28, 2000].
Longo F
Tumori; 2000; 86(6):A13-8. PubMed ID: 11271674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
